Goldman Sachs’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-183,678
| Closed | -$3.26M | – | 4368 |
|
|
2018
Q3 | $3.26M | Buy |
183,678
+21,006
| +13% | +$373K | ﹤0.01% | 2642 |
|
|
2018
Q2 | $2.25M | Sell |
162,672
-202,360
| -55% | -$2.79M | ﹤0.01% | 2838 |
|
|
2018
Q1 | $3.32M | Buy |
365,032
+191,273
| +110% | +$1.74M | ﹤0.01% | 2580 |
|
|
2017
Q4 | $744K | Buy |
173,759
+162,498
| +1,443% | +$696K | ﹤0.01% | 3274 |
|
|
2017
Q3 | $16K | Sell |
11,261
-419,733
| -97% | -$596K | ﹤0.01% | 4207 |
|
|
2017
Q2 | $646K | Buy |
430,994
+393,975
| +1,064% | +$591K | ﹤0.01% | 3383 |
|
|
2017
Q1 | $95K | Sell |
37,019
-46,421
| -56% | -$119K | ﹤0.01% | 4130 |
|
|
2016
Q4 | $213K | Buy |
83,440
+31,696
| +61% | +$80.9K | ﹤0.01% | 3864 |
|
|
2016
Q3 | $160K | Sell |
51,744
-24,091
| -32% | -$74.5K | ﹤0.01% | 4021 |
|
|
2016
Q2 | $243K | Sell |
75,835
-53,108
| -41% | -$170K | ﹤0.01% | 3746 |
|
|
2016
Q1 | $400K | Buy |
128,943
+112,302
| +675% | +$348K | ﹤0.01% | 3358 |
|
|
2015
Q4 | $67K | Buy |
16,641
+3,401
| +26% | +$13.7K | ﹤0.01% | 4111 |
|
|
2015
Q3 | $61K | Sell |
13,240
-13,313
| -50% | -$61.3K | ﹤0.01% | 4296 |
|
|
2015
Q2 | $138K | Buy |
26,553
+1,420
| +6% | +$7.38K | ﹤0.01% | 4193 |
|
|
2015
Q1 | $158K | Buy |
+25,133
| New | +$158K | ﹤0.01% | 3990 |
|
|
2014
Q4 | – | Sell |
-14,737
| Closed | -$90K | – | 4751 |
|
|
2014
Q3 | $90K | Sell |
14,737
-86,147
| -85% | -$526K | ﹤0.01% | 4254 |
|
|
2014
Q2 | $665K | Buy |
100,884
+88,077
| +688% | +$581K | ﹤0.01% | 3196 |
|
|
2014
Q1 | $305K | Sell |
12,807
-14,732
| -53% | -$351K | ﹤0.01% | 3672 |
|
|
2013
Q4 | $294K | Buy |
27,539
+3,323
| +14% | +$35.5K | ﹤0.01% | 3708 |
|
|
2013
Q3 | $323K | Buy |
24,216
+10,487
| +76% | +$140K | ﹤0.01% | 3576 |
|
|
2013
Q2 | $180K | Buy |
+13,729
| New | +$180K | ﹤0.01% | 3670 |
|